Review Article
The Role of Adenosine in Pulmonary Vein Isolation: A Critical Review
Table 2
Cryoablation and laser ablation studies addressing adenosine use in PVI.
| |
Study | | Comparison
groups | | veins | Energy | pAF | Waiting time
(minutes) | Adenosine
dose (mg) | Reconnected
patients (%) | Reconnected
veins (%) | Follow-up
(months) | AF freedom (%) | | Recurrence in
patients with DC (%) |
|
Chierchia et al.
2009 [22] | 39 | — | — | 149 |
Cryo | 100% | 15 | 20 | 5 (13%) | 7 (4.6%) | 6 | 77% | — | 2/5 (40%) |
|
Van Belle et al.
2012 [23] | 99 | A given | 34 | 132 |
Cryo | 100% | 0 | 25 | 7 (21%) | 9 (8%) | 17 ± 5 | 68% | 0.04 | — | | A not given | 65 | — |
Cryo | 100% | — | — | — | — | 17 ± 5 | 46% | — |
|
Ciconte et al.
2014 [24] | 50 | A given | — | 200 |
Cryo | 82% | 30 | 18–30 | 6 (12%) | 8 (4%) | 7 ± 1.7 | 86% | — | 0 (0%) |
|
Kumar et al.
2015 [25] | 90 | A given | 45 | 179 |
Cryo | 79 | 30 | 15 ± 3 | — | 8 (4.5%) | 13 ± 1 | 84% | NS | 0 (0%) | | A not given | 45 | 179 |
Cryo | — | | — | — | 12 ± 2 | 79% | — |
|
Compier et al.
2015 [26] | 98 | A given | 36 | 143 |
Cryo | 86% | 30 | 17 ± 5 | 15 (42%) | 20 (14%) | 12 ± 1 | 83% | 0.02 | — | | A not given (historical cohort) | 62 | — |
Cryo | 90% | — |
— |
— |
— | 11 ± 1 | 60% | — |
|
Kumar et al.
2014 [27] | 60 | A given | 40 | 151 |
Cryo | 87.5% | 30 | 12 ± 3 | 4 (2.5%) | 4 (5%) | 11 ± 3 | 85% | NS | — | | A given | 20 | 80 | Laser | 90% | 30 | 12 ± 3 | 7 (35%) | 11 (13.8%) | 9 ± 2 | 85% | — |
|
Üçer et al.
2015 [28] | 26 | A given | — | 102 | Laser | 100% | 30 | 18 | 5 (20%) | 6 (6.7%) | 6 | 81% | — | 2/5 (40%) |
|
|
A: adenosine; AF: atrial fibrillation; DC: dormant conduction; pAF: paroxysmal atrial fibrillation.
|
